Mototaka Sato1, Masafumi Kashii2, Atsuki Matsukawa1, Ryoya Mizuno1, Mai Akiyama1, Takashi Kamatani3, Satoshi Kamido4, Norichika Ueda1, Jiro Nakayama5, Norihide Tei1, Hideki Yoshikawa3, Osamu Miyake1. 1. Department of Urology, Toyonaka Municipal Hospital, Osaka, Japan. 2. Department of Orthopaedic Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibaharacho, Toyonaka, Osaka, 560-8565, Japan. kashii-masafumi-dt@alumni.osaka-u.ac.jp. 3. Department of Orthopaedic Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibaharacho, Toyonaka, Osaka, 560-8565, Japan. 4. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. 5. Department of Urology, Suita Tokushukai Hospital, Osaka, Japan.
Abstract
PURPOSE: To evaluate the utility of vertebral Hounsfield unit (HU) values from computed tomography (CT) in cancer staging as a supplementary screening tool for bone health among prostate cancer (PCa) patients. METHODS: T-scores of bone mineral density (BMD) in each lumbar vertebra (L1-L4) and hip for newly diagnosed PCa patients (N = 139) were measured using dual-energy X-ray absorptiometry (DXA). The degenerative changes in each lumbar vertebra were assessed, and the HU values of trabecular bone in axial CT images of each vertebral body (vertebral CT-HU value) were measured using staging CT. RESULTS: 556 vertebrae were analyzed. 326 of 556 (59%) lumbar vertebrae had degenerative changes. The vertebral CT-HU value was positively correlated with the lumbar BMD T-score, with higher correlation coefficients observed in vertebrae without degenerative changes (r = 0.655, N = 230) when compared to vertebrae with degenerative changes (r = 0.575, N = 326). The thresholds matching BMD T-scores of - 2.0 and - 1.5 set by cancer treatment-induced bone loss guidelines were 95 HU and 105 HU, respectively. Based on the intervention threshold (lumbar BMD T-score < - 1.5), 15.1% of PCa patients required osteoporosis treatment; and, this value increased to 30.9% when L1-L4 CT-HU thresholds that corresponded to BMD T-score < - 1.5 were used. CONCLUSION: Lumbar BMD values from DXA may not reflect true bone health in PCa patients who often have lumbar degenerative diseases. Thresholds based on the vertebral CT-HU value can be used as a supplementary method to identify PCa patients who need anti-osteoporosis drugs.
PURPOSE: To evaluate the utility of vertebral Hounsfield unit (HU) values from computed tomography (CT) in cancer staging as a supplementary screening tool for bone health among prostate cancer (PCa) patients. METHODS: T-scores of bone mineral density (BMD) in each lumbar vertebra (L1-L4) and hip for newly diagnosed PCa patients (N = 139) were measured using dual-energy X-ray absorptiometry (DXA). The degenerative changes in each lumbar vertebra were assessed, and the HU values of trabecular bone in axial CT images of each vertebral body (vertebral CT-HU value) were measured using staging CT. RESULTS: 556 vertebrae were analyzed. 326 of 556 (59%) lumbar vertebrae had degenerative changes. The vertebral CT-HU value was positively correlated with the lumbar BMD T-score, with higher correlation coefficients observed in vertebrae without degenerative changes (r = 0.655, N = 230) when compared to vertebrae with degenerative changes (r = 0.575, N = 326). The thresholds matching BMD T-scores of - 2.0 and - 1.5 set by cancer treatment-induced bone loss guidelines were 95 HU and 105 HU, respectively. Based on the intervention threshold (lumbar BMD T-score < - 1.5), 15.1% of PCa patients required osteoporosis treatment; and, this value increased to 30.9% when L1-L4 CT-HU thresholds that corresponded to BMD T-score < - 1.5 were used. CONCLUSION: Lumbar BMD values from DXA may not reflect true bone health in PCa patients who often have lumbar degenerative diseases. Thresholds based on the vertebral CT-HU value can be used as a supplementary method to identify PCa patients who need anti-osteoporosis drugs.
Authors: Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman Journal: J Clin Densitom Date: 2008 Jan-Mar Impact factor: 2.617
Authors: B Hager; K Kraywinkel; B Keck; A Katalinic; M Meyer; S R Zeissig; R Scheufele; M P Wirth; J Huber Journal: Prostate Cancer Prostatic Dis Date: 2016-09-13 Impact factor: 5.554
Authors: Perry J Pickhardt; B Dustin Pooler; Travis Lauder; Alejandro Muñoz del Rio; Richard J Bruce; Neil Binkley Journal: Ann Intern Med Date: 2013-04-16 Impact factor: 25.391
Authors: Bo Abrahamsen; Morten F Nielsen; Peter Eskildsen; Jens Thorup Andersen; Steen Walter; Kim Brixen Journal: BJU Int Date: 2007-10 Impact factor: 5.588
Authors: Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman Journal: J Bone Oncol Date: 2017-03-23 Impact factor: 4.072
Authors: Luisella Cianferotti; Francesco Bertoldo; Marco Carini; John A Kanis; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Jean-Yves Reginster; Rene Rizzoli; Maria Luisa Brandi Journal: Oncotarget Date: 2017-05-18